Human Chorionic Gonadotropin Supplementation Prior to In-vitro Fertilization Treatment in Poor Responders

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2010 by Hadassah Medical Organization.
Recruitment status was  Not yet recruiting
Sponsor:
Information provided by:
Hadassah Medical Organization
ClinicalTrials.gov Identifier:
NCT01205009
First received: August 30, 2010
Last updated: March 1, 2011
Last verified: September 2010

August 30, 2010
March 1, 2011
April 2011
March 2012   (final data collection date for primary outcome measure)
number of oocytes retrieved [ Time Frame: 1 month ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01205009 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Human Chorionic Gonadotropin Supplementation Prior to In-vitro Fertilization Treatment in Poor Responders
Not Provided

In an era of delayed fertility plans, there is increasing need for fertility treatment in older women with poor response. Human chorionic gonadotropin (hCG) supplementation prior to treatment, as a thecal stimulant, may improve folliculogenesis and ovarian response.

Not Provided
Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Infertility
Drug: Ovitrelle
One dose of Ovitrelle 250 mcg
  • Active Comparator: Ovitrelle supplemantation
    The women will be given 250 mcg of Ovitrelle prior to their IVF cycle
    Intervention: Drug: Ovitrelle
  • No Intervention: no Ovitrelle supplementation
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Not yet recruiting
100
Not Provided
March 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • women >39 years on IVF treatment

Exclusion Criteria:

  • polycystic ovary syndrome
  • Any allergy to injection of human chorionic gonadotropin before
Female
40 Years to 45 Years
No
Contact: Mushira Aboo Dia, , MD mushiraa@gmail.com
Contact: Hadas Lemberg, PhD 00 972 2 6777572 lhadas@hadassah.org.il
Israel
 
NCT01205009
hCGpoorresp-HMO-CTIL
Not Provided
Arik Tzukert, Hadassah Medical Center
Hadassah Medical Organization
Not Provided
Principal Investigator: Mushira Aboo Dia, MD Hadassah Medical Center
Hadassah Medical Organization
September 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP